share_log

Earnings Call Summary | Sharecare(SHCR.US) Q4 2023 Earnings Conference

Earnings Call Summary | Sharecare(SHCR.US) Q4 2023 Earnings Conference

業績電話會議摘要 | Sharecare (SHCR.US) 2023 年第四季度業績會議
moomoo AI ·  03/28 21:22  · 電話會議

The following is a summary of the Sharecare, Inc. (SHCR) Q4 2023 Earnings Call Transcript:

以下是Sharecare, Inc.(SHCR)2023年第四季度業績電話會議記錄摘要:

Financial Performance:

財務業績:

  • Sharecare reported revenues of $105 million for Q4 and $445 million for 2023, achieving cash flow breakeven by the end of 2023 as targeted.

  • Adjusted EBITDA for the quarter was $3 million, and $16.5 million for the year.

  • A disputed contract led to the elimination of nonperforming contracts and caused a $14 million reduction in Q4 revenue and $6 million decrease in adjusted EBITDA.

  • Sharecare報告稱,第四季度收入爲1.05億美元,2023年收入爲4.45億美元,目標是到2023年底實現現金流盈虧平衡。

  • 本季度調整後的息稅折舊攤銷前利潤爲300萬美元,全年調整後的息稅折舊攤銷前利潤爲1,650萬美元。

  • 一份有爭議的合同導致不良合同的取消,並導致第四季度收入減少了1400萬美元,調整後的息稅折舊攤銷前利潤減少了600萬美元。

Business Progress:

業務進展:

  • The company signed its first Medicaid contract, is in advanced discussions for a new health navigation platform, and is making headway to support risk-bearing arrangements with their data analytics capability.

  • Sharecare is preparing for the launch of a holistic GLP-1 weight loss solution and is actively contracting with reinsurance partners and risk-bearing entities.

  • A resolution to a current disputed contract is expected to help maintain cash flow breakeven.

  • The company is developing a unique navigation tool for Medicaid recipients, planning to win more RFPs, and aiming to improve solutions for employers and government customers.

  • Despite a difficult situation with a disputed contract, Sharecare anticipates future growth given a successful Q4 in provider performance and strong operations in life sciences.

  • 該公司簽署了第一份醫療補助合同,正在就新的健康導航平台進行深入討論,並正在利用其數據分析能力在支持風險承擔安排方面取得進展。

  • Sharecare正在爲推出全面的 GLP-1 減肥解決方案做準備,並正在積極與再保險合作伙伴和風險承擔實體簽訂合同。

  • 預計解決當前有爭議的合同將有助於維持現金流的盈虧平衡。

  • 該公司正在爲醫療補助接受者開發一種獨特的導航工具,計劃贏得更多的RFP,並旨在改善爲僱主和政府客戶提供的解決方案。

  • 儘管合同存在爭議,處境艱難,但鑑於第四季度供應商的成功業績和生命科學領域的強勁運營,Sharecare預計未來的增長。

More details: Sharecare IR

更多詳情: Sharecare IR

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.

提示:本文由 AI 生成。無法完全保證內容的準確性。欲了解更多詳情,請訪問投資者關係網站。本文僅供投資者參考,不構成任何投資建議。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論